The Biologics and Biosimilars Landscape in the Middle East and North Africa
The Middle East and North Africa region has seen significant growth in the biopharmaceutical sector over the past decade. Several countries in the region have prioritized healthcare and the development of domestic biologics and biosimilars industries. According to a recent report, the MENA biologics . was valued at $3.3 billion in 2020 and is projected to grow to over $6 billion by 2026, reflecting an annual growth rate of over 11%. This rapid expansion can be attributed to rising healthcare budgets, increasing demand for specialized therapies, and supportive regulatory frameworks emerging across the region.
Saudi Arabia Emerges as Regional Front-Runner
Saudi Arabia has emerged as the clear leader in the MENA Biologics and Biosimilars .. In 2022, the kingdom launched its National Biotechnology Strategy, aimed at developing a robust local industry and reducing reliance on imported biopharmaceuticals. The strategy targets over $6 billion in annual biotech sales by 2030 and creating 40,000 high-skilled jobs. Saudi Arabia also established the Saudi Authority for Intellectual Property to streamline patent approvals for biologics. Several Saudi companies are gaining approvals to manufacture biosimilars locally through technology transfer partnerships. In addition, the kingdom has raised healthcare spending significantly and implemented price controls on medicines to enhance biosimilar adoption. These industry-friendly policies are attracting major global biotech investments to Saudi biotech hubs like Taif and Jeddah.
Strong Growth Anticipated Across GCC
Building on Saudi Arabia's successes, other Gulf Cooperation Council countries are boosting their biologics capabilities. The United Arab Emirates established a MENA Biologics and Biosimilars excellence centre in 2016 and approved several locally-made biosimilars. Abu Dhabi launched a $272 million healthcare industrial fund this year focused on biotech startups. Kuwait initiated a cabinet-level committee to develop biomanufacturing and streamline patent laws. Oman and Bahrain have also unveiled biosimilars strategies in pursuit of self-sufficiency and cost savings. With GCC countries investing heavily in science education and cutting-edge research infrastructure, the regional biotech industry is projected to undergo further robust expansion in the coming years.
North African Nations Join the Fray
North African countries are no exception to the trend of growing biologics independence. Egypt, which biologic consumption has doubled in the past five years, aims to produce 20% of medicines locally by 2030. To this end, it has established technology transfer partnerships with multinationals and expanded funding schemes for biotech ventures. Meanwhile, Morocco has facilitated the approval of over a dozen biosimilars, with factories now exported over $300 million worth of biologics annually. Algeria formed a taskforce promoting localized research for biosimilar versions of high-consumption medicines. Tunisia's initiative to boost biosimilars use across public hospitals saved the government over $10 million last year alone. With the rebound in hydrocarbon revenues fueling development budgets, North African biotech industries show renewed promise to address regional needs sustainably.
Regulatory Reforms Catalyze Growth
Regulatory reforms across MENA have been instrumental in creating conducive environments for scaled-up biologics production and . uptake of biosimilars. Saudi Arabia established the Saudi Food and Drug Authority (SFDA) in 2005, which has since approved over 40 biosimilars, and provides a single window for expedited import approvals. The UAE Health Authority has enabled real-time coordination between manufacturers and approving bodies, cutting time-to-.. Morocco instituted a biosimilars special committee reducing review periods from years to months. Algeria restructured its regulatory agency and implemented pricing guidelines facilitating biosimilar proliferation. Such progressive guidelines have strengthened investor confidence, catalyzing billions in public and private sector financing. Looking ahead, regional alignment of requirements and mutual recognition of approvals will further accelerate business growth.
Outlook: A Promising Industry in the Making
The prospects for growth in the MENA Biologics and Biosimilars . over the coming decade appear exceptionally bright. Tailwinds from continued healthcare investments, intensifying R&D collaborations, regulatory modernizations, and societal acceptance of biosimilars all point to an exponential rise in both manufacturing capacity and cost-effective access to life-saving medicines. With new strategic objectives, financing vehicles, technology transfer agreements, and exchange programs unfolding each year, the region is increasingly integrated in global biopharma value chains. Successful models emerging across nations will likely be replicated and scaled up. Progress achieved thus far proves the immense untapped potential within the MENA region to become self-reliant in specialized biologics while maintaining the highest safety and efficacy standards. The horizons of biopharma and patient care across the Middle East and North Africa continue expanding.
Explore More Related Article On- Sterile Injectables Market
Unlock More Insights—Explore the Report in the Language You Prefer
About Author:
Priya Pandey, is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)
Comments
0 comment